FDA approves Hulio biosimilar (adalimumab-fkjp)
-
Last Update: 2020-07-16
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The U.SFDA has approved hulio ®, a biological analogue of the Humira ®, the U.SFDA announced today!----Hulio pre-installed syringes and auto-injectable syringes can treat rheumatoid arthritis, juvenile isoarthritis, psoriasis arthritis, aggressive spina bifida, adult Crohn's disease, ulcerative colitis and plaque-like psoriasisHumira and Hulio are both TNF-alpha inhibitorsRajiv Malik, president of mylan,, said: "As the world's best-selling drug, the safety and effectiveness of Humira has been widely recognizedwe are pleased that the FDA has approved Humira biosimilar Hulio, which will provide a relatively inexpensive treatment option for U.Spatients with chronic inflammatory diseases."tumor necrosis factor (TNF) alpha is a cytokine that plays a role in a variety of biological effects, mainly produced by mononucleoblasts, macrophages and thymus-dependent lymphocytes, divided into dissolved and membrane binding typesTNF-alpha causes a series of cytokine changes by binding specifically with its receptor (TNFR), which in turn promotes the development of diseases such as limited enteritis and rheumatoid arthritis
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
